Holen Sie sich die Stockscreener-App
0.4701
2.47%
-0.0202
Handel nachbörslich:
.47
-0.0001
-0.02%
Schlusskurs vom Vortag:
$0.4903
Offen:
$0.471
24-Stunden-Volumen:
192.07K
Relative Volume:
0.60
Marktkapitalisierung:
$11.34M
Einnahmen:
$81.89M
Nettoeinkommen (Verlust:
$-55.20M
KGV:
-
EPS:
-
Netto-Cashflow:
$-67.40M
1W Leistung:
-8.39%
1M Leistung:
-2.23%
6M Leistung:
-82.02%
1J Leistung:
-85.77%
1-Tages-Spanne:
$0.4511
$0.494
1-Wochen-Bereich:
$0.4511
$0.5893
52-Wochen-Spanne:
$0.4393
$5.75
Turnstone Biologics Corp Stock (TSBX) Company Profile
Firmenname
Turnstone Biologics Corp
Sektor
Branche
Telefon
347-897-5988
Adresse
9310 ATHENA CIRCLE, SUITE 300, LA JOLLA
Vergleichen Sie TSBX mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
| TSBX | 0.4701 | 11.34M | 81.89M | -55.20M | -67.40M | 0.00 |
| VRTX | 467.01 | 119.87B | 10.63B | -479.80M | -1.35B | 13.33 |
| REGN | 762.00 | 83.27B | 13.85B | 4.65B | 3.32B | 35.06 |
| ARGX | 567.90 | 33.96B | 1.86B | -40.29M | -1.28B | -4.16 |
| ALNY | 232.27 | 30.18B | 2.09B | -332.26M | 16.06M | -4.14 |
| BNTX | 101.83 | 24.42B | 3.30B | -501.07M | 1.03B | 11.54 |
Turnstone Biologics Corp Aktie (TSBX) Neueste Nachrichten
Turnstone Biologics Faces Financial and Operational Challenges - TipRanks
Turnstone Biologics Corp. Reports Third Quarter 2024 Financial Results and Provides Recent Business Highlights - The Manila Times
Turnstone Biologics Reports 25% Response Rate in Cancer Trial, Extends Cash Runway to 2026 | TSBX Stock News - StockTitan
Turnstone advances TIL therapy for solid tumors at SITC meeting By Investing.com - Investing.com Australia
Turnstone advances TIL therapy for solid tumors at SITC meeting - Investing.com
Turnstone Biologics Presents Preclinical Data Highlighting Potential for Selected Tumor-Infiltrating Lymphocyte (TIL) Therapy in Solid Tumors at the 2024 Society for Immunotherapy of Cancer (SITC) Annual Meeting - The Manila Times
Turnstone Biologics Reveals Breakthrough TIL Cancer Treatment Data at SITC 2024 | TSBX Stock News - StockTitan
Warning: TSBX is at high risk of performing badly - MSN
Turnstone Biologics (NASDAQ:TSBX) & Recursion Pharmaceuticals (NASDAQ:RXRX) Critical Contrast - Defense World
BofA downgrades Turnstone stock, citing wait-and-see approach until 2025 data - Investing.com
Turnstone fires most staff in bid to to extend runway - The Pharma Letter
Turnstone Biologics Streamlines Operations and Leadership - Yahoo Finance
Turnstone Biologics announces strategic cuts and focus shift - Investing.com
Turnstone Biologics Announces Strategic Restructuring to Prioritize Portfolio and Extend Financial Runway - ForexTV.com
Turnstone Biologics stock plunges to 52-week low of $0.45 - Investing.com
Turnstone Biologics Corp. (NASDAQ:TSBX) Short Interest Update - Defense World
Turnstone Biologics stock hits 52-week low at $0.58 amid sharp decline - Investing.com
Analyzing Organovo (NASDAQ:ONVO) & Turnstone Biologics (NASDAQ:TSBX) - Defense World
Reviewing Krystal Biotech (NASDAQ:KRYS) & Turnstone Biologics (NASDAQ:TSBX) - Defense World
Turnstone Biologics stock plunges to 52-week low of $0.67 - Investing.com
Turnstone Biologics stock plunges to 52-week low of $0.67 By Investing.com - Investing.com Canada
Taking on analysts’ expectations and winning: Turnstone Biologics Corp (TSBX) - SETE News
Investor’s Delight: Turnstone Biologics Corp (TSBX) Closes Strong at 0.70, Up 1.15 - The Dwinnex
Is Turnstone Biologics Corp (TSBX) a good investment opportunity? - US Post News
Turnstone Biologics Corp. (NASDAQ:TSBX) Sees Significant Increase in Short Interest - Defense World
Turnstone Biologics stock plunges to 52-week low of $0.72 - Investing.com
Turnstone Biologics price target lowered to $10 from $12 at BofA - TipRanks
Tourmaline Bio (NASDAQ:TRML) versus Turnstone Biologics (NASDAQ:TSBX) Head-To-Head Review - Defense World
The time has not yet come to remove your chips from the table: Turnstone Biologics Corp (TSBX) - SETE News
Turnstone Biologics Corp’s results are impressive - US Post News
Turnstone Biologics (NASDAQ:TSBX) Price Target Cut to $3.75 by Analysts at Piper Sandler - Defense World
Turnstone Biologics shares target cut by Piper Sandler with no rating change - Investing.com
TSBX’s Stock Market Adventure: -70.07% YTD Growth Amidst Volatility - The InvestChronicle
Market Momentum: Turnstone Biologics Corp (TSBX) Registers a -8.24 Decrease, Closing at 0.76 - The Dwinnex
Turnstone Biologics price target lowered to $3.75 from $20 at Piper Sandler - TipRanks
SVB Securities slashes price target on Turnstone Biologics Corp [TSBX] – find out why. - The DBT News
Turnstone Biologics (NASDAQ:TSBX) Releases Quarterly Earnings Results, Misses Estimates By $0.08 EPS - Defense World
Take off with Turnstone Biologics Corp (TSBX): Get ready for trading - SETE News
Turnstone Biologics stock plunges to 52-week low of $1.36 By Investing.com - Investing.com Canada
Why Is Turnstone Biologics Stock Trading Lower On Thursday?Turnstone Biologics (NASDAQ:TSBX) - Benzinga
Turnstone Biologics stock plunges to 52-week low of $1.36 - Investing.com
Turnstone reports positive early trial results for cancer therapy - Investing.com
Why Is Turnstone Biologics (TSBX) Stock Down 38% Today? - InvestorPlace
Turnstone Biologics Reports Encouraging Phase 1 Results - TipRanks
Turnstone Biologics Corp. Reports Second Quarter 2024 Financial Results and Provides Recent Business Highlights - ForexTV.com
Turnstone Biologics reports Q2 EPS (92c), consensus (93c) - TipRanks
Turnstone Biologics Corp. Reports Positive Initial Data from Phase 1 Trial of TIDAL-01 in Metastatic Colorectal Cancer - StockTitan
Turnstone Biologics Corp. (TSBX): This Penny Stock is a ‘Strong Buy’ According to Analysts - Insider Monkey
Turnstone Biologics Corp. (NASDAQ:TSBX) Short Interest Down 20.5% in June - MarketBeat
Can you still get a good price for Turnstone Biologics Corp (TSBX) Shares at this point? – US Post News - US Post News
Finanzdaten der Turnstone Biologics Corp-Aktie (TSBX)
Umsatz
Nettogewinn
Free Cashflow
ENV
4.27%
0.88%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Kapitalisierung:
|
Volumen (24h):